MEDICINOVA
medicinova.jp
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
ニュース 研究開発 IRニュース メディア/イベント 企業情報 トップメッセージ 理念・経営方針 会社概要 経営メンバー 沿革 コーポレート・ガバナンス メディシノバを知る ビジネスモデル 数字で見る日本と米国の違い FDA（米国食品医薬品局）の指定承認 開発パイプラインについて 現在進行中の臨床治験 MN-166 ALS（筋萎縮性側索硬化症) DCM（頸椎症性脊髄症） CIPN（化学療法誘発性末梢神経障害） オンコロジー/グリオブラストーマ ARDS（急性呼吸窮迫症候群） MN-001 NAFLD（非アルコール性脂肪性肝疾患) 糖尿病に合併した脂質異常症 株主・投資家情報 IRニュース…
News
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia
Read more
Report
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: M...
Read more
Report
MediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket
MediciNova announced Phase 2 results for MN-001 in patients with hypertriglyceridemia and non-alcoholic fatty liver disease associated with type 2 diabetes. The drug demonstrated statistically significant improvements in HDL cholesterol and HDL particle c
Read more
Report
Report
MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment
Read more
Report
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: M...
Read more
Report
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
Detailed price information for Medicinova Inc (MNOV-Q) from The Globe and Mail including charting and trades.
Read more
Report
MediciNova Added to the NASDAQ Biotechnology Index
LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will
Read more
Report